DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20205849

Study of the price variation analysis of proton pump inhibitors available in Indian pharmaceutical market

Rabi Bhushan, Anupam Kishore, Akash Chandra, Ajay Kumar, Haribansh kumar Singh

Abstract


Background: In now day’s proton pump inhibitors are prescribing more and more by Indian physicians not only in peptic ulcer, gastroesophageal reflux disease, gastritis but also along with non-steroidal anti-inflammatory drugs to overcome the side effects as gastric irritation and discomfort by non-steroidal anti-inflammatory drugs. There are many brands of PPI drugs available in Indian market. Costly drugs can lead to economic burden which results in decreased compliance or even non-compliance. Non–compliance leads to incomplete treatment which tends to increase morbidity. Increase in the patient medication cost was found to associated with decreased adherence to prescription medication. Hence this study was done to assess the cost variation of proton pump inhibitors (PPI) drugs.

Methods: The maximum and minimum price of each brand of the drug in INR was noted by using Drug Today January to April 2020 edition, Vol-1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of 10 tablets/capsules was calculated in case of oral drug. At last the cost ratio and percentage cost variation of various brands was compared.

Results: Percentage variation in cost for proton pump inhibitors marketed in india was found to be tablet/capsule Esomeprazole [20mg]: 297.65, tablet/capsule Esomeprazole [40mg]: 344.41, capsule/tablet Omeprazole [10mg]: 74.51, capsule/tablet Omeprazole [20mg]: 542, Tablet/capsule Pantoprazole [40mg]: 3297.33, tablet/capsule Rabeprazole [10mg]: 1160, tablet/capsule Rabeprazole [20mg]: 1101.05, capsule/tablet Lansoprazole [15mg]: 306.69, capsule/tablet Lansoprazole [30mg]: 336.33,   capsule/tablet Dexlansoprazole [60mg]: 7.69.

Conclusions: Capsule Pantoprazole [40mg] shows highest cost ratio and percentage cost variation as 33.97 and 3297.33. While capsule Dexlansoprazole [60mg] shows lowest cost ratio and percentage cost variation as 1.07 and 7.69.


Keywords


Compliance, Cost ratio, PPI, Percentage cost variation

Full Text:

PDF

References


Forte JG, Lee HC. "Gastric adenosine triphosphatases: A review of their possible role in HCl secretion". Gastroenterol. 1977;73(4 Pt 2): 921-6.

Snaeder W. Drug prototypes and their exploitation. Wiley. 1996:414–5.

Hemenway JN. "Case Study: Omeprazole (Prilosec)". Prodrugs. Biotechnology: Pharmaceutical Aspects. 2007:1313–21.

Olbe L, Carlsson E, Lindberg P. "A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole". Nature Reviews. Drug Discovery. 2003;2(2):132-9.

Senn-Bilfinger J, Sturm E. "The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole". Analogue-based Drug Discovery. 2006:115-36.

Lindberg P, Carlsson E. "Esomeprazole in the Framework of Proton-Pump Inhibitor Development". Analogue-based Drug Discovery. 2006:81–113.

Shin JM, Munson K, Vagin O, Sachs G."The gastric HK-ATPase: Structure, function, and inhibition". Pflügers Archiv - European J Physiol. 2008;457(3): 609-22.

Sachs G, Shin JM, Vagin O, Lambrecht N. Yakubov I, Munson K."The Gastric H,K ATPase as a Drug Target". J Clinic Gastroenterol. 2007;41(Suppl 2): S226-42.

Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR.How patients cost-sharing trends affects adherence and out comes: a literature review: PT. 2012;37:45-55.

Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004; 17:80-3.

Sanchez LS. Pharmacoeconomics: Principles, methods and applications. In: Dipiro JT, Talbert RL,. Yee GC, Matzke GR, Wells BG, Posey ML, Eds. Pharmacotherapy: A pathophysiological approach. 7th Ed. McGraw Hill; New York; 2008:1-2.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Pharmacol. 2014:3:954-7.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, Editors. A Textbook of Clinical Pharmacy Practice. 1st Ed. Himayatnagar, Hyderabad: Orient Longman; 2004;72:3.

Creese A, Kotwani A, Kutzin J, Pillay A. Evauating pharmaceuticals for health policy in low and middle-income country settings. In: Freemantle N, Hill S, eds. Evaluating pharmaceuticals for health policy and reimbursement. Massachusetts, USA: Blackwell Publication; (in collaboration with WHO Geneva); 2004:227-43.

Mahal A, Karan A, Engelgau M. The Economic Implications of Non-Communicable Disease for India. Washington, DC: World Bank.2010. Available at http://siteresources.worldbank.org/HEALTHNUTRI TIONANDPOPULATION/Resources/281627- 1095698140167/EconomicImplicationsofNCDforIn dia.pdf.

Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51:13-6.

Drug Cost Control Order, 2013, Government of India. Available at http://www.nppaindia.nic.in/DPCO2013.pdf.